245 related articles for article (PubMed ID: 28122377)
1. Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview.
Menna P; Salvatorelli E
Chemotherapy; 2017; 62(3):159-168. PubMed ID: 28122377
[TBL] [Abstract][Full Text] [Related]
2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
3. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
Vejpongsa P; Yeh ET
J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity.
Vejpongsa P; Yeh ET
Clin Pharmacol Ther; 2014 Jan; 95(1):45-52. PubMed ID: 24091715
[TBL] [Abstract][Full Text] [Related]
5. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
Kaklamani VG; Gradishar WJ
Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S26-33. PubMed ID: 12756076
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
Gianni L; Salvatorelli E; Minotti G
Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Chung WB; Youn HJ
Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).
Orditura M; Quaglia F; Morgillo F; Martinelli E; Lieto E; De Rosa G; Comunale D; Diadema MR; Ciardiello F; Catalano G; De Vita F
Oncol Rep; 2004 Sep; 12(3):549-56. PubMed ID: 15289836
[TBL] [Abstract][Full Text] [Related]
9. Chronic heart damage following doxorubicin treatment is alleviated by lovastatin.
Henninger C; Huelsenbeck S; Wenzel P; Brand M; Huelsenbeck J; Schad A; Fritz G
Pharmacol Res; 2015 Jan; 91():47-56. PubMed ID: 25462173
[TBL] [Abstract][Full Text] [Related]
10. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
Cardinale D; Colombo A; Bacchiani G; Tedeschi I; Meroni CA; Veglia F; Civelli M; Lamantia G; Colombo N; Curigliano G; Fiorentini C; Cipolla CM
Circulation; 2015 Jun; 131(22):1981-8. PubMed ID: 25948538
[TBL] [Abstract][Full Text] [Related]
11. Rationale and strategy for prevention of anthracycline cardiotoxicity with the bisdioxopiperazine, ICRF-187.
Green MD
Pathol Biol (Paris); 1987 Jan; 35(1):49-53. PubMed ID: 3550612
[TBL] [Abstract][Full Text] [Related]
12. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.
Burridge PW; Li YF; Matsa E; Wu H; Ong SG; Sharma A; Holmström A; Chang AC; Coronado MJ; Ebert AD; Knowles JW; Telli ML; Witteles RM; Blau HM; Bernstein D; Altman RB; Wu JC
Nat Med; 2016 May; 22(5):547-56. PubMed ID: 27089514
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator.
Rudzinski T; Ciesielczyk M; Religa W; Bednarkiewicz Z; Krzeminska-Pakula M
Europace; 2007 May; 9(5):278-80. PubMed ID: 17383986
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial resveratrol and quercetin polymeric micelles mitigate doxorubicin induced cardiotoxicity in vitro and in vivo.
Cote B; Carlson LJ; Rao DA; Alani AWG
J Control Release; 2015 Sep; 213():128-133. PubMed ID: 26160305
[TBL] [Abstract][Full Text] [Related]
15. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
Conklin KA
Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
[TBL] [Abstract][Full Text] [Related]
16. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
Doyle JJ; Neugut AI; Jacobson JS; Grann VR; Hershman DL
J Clin Oncol; 2005 Dec; 23(34):8597-605. PubMed ID: 16314622
[TBL] [Abstract][Full Text] [Related]
18. Heart Failure in Relation to Anthracyclines and Other Chemotherapies.
Agunbiade TA; Zaghlol RY; Barac A
Methodist Debakey Cardiovasc J; 2019; 15(4):243-249. PubMed ID: 31988684
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin liposomal pegylated: new preparation. Breast cancer: not just a question of short-term cardiac effects.
Prescrire Int; 2004 Jun; 13(71):90-1. PubMed ID: 15233142
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer.
Caram MEV; Guo C; Leja M; Smerage J; Henry NL; Giacherio D; Rubenfire M; Schott A; Davis M; Hayes DF; Van Poznak C; Cooney KA; Hertz DL; Banerjee M; Griggs JJ
Breast Cancer Res Treat; 2015 Jul; 152(1):163-172. PubMed ID: 26050157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]